Global Viral Partnering 2012-2018: Deal trends, players and financials

Publisher Name :
Date: 01-Oct-2018
No. of pages: 500
Inquire Before Buying

"Delivery of this report will take 1-3 days after purchase."

The Global Viral Partnering 2012-2018: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the viral partnering deals and agreements entered into by the worlds leading healthcare companies

Global Viral Partnering 2012 to 2018 provides the full collection of Viral disease deals signed between the world's pharmaceutical and biotechnology companies since 2012.

Trends in Viral partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Viral partnering agreement structure

Viral partnering contract documents

Top Viral deals by value

Most active Viral dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Viral disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Viral deals.

The report presents financial deal terms values for Viral deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Viral dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Viral dealmaking since 2012 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Viral deals since 2012. Deals are listed by headline value. The chapter includes the top 25 most active Viral dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Viral deals since 2012 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Viral partnering deals by specific Viral target announced since 2012. The chapter is organized by specific Viral therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Viral partnering deals signed and announced since 2012. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Viral partnering and dealmaking since 2012.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Viral technologies and products.

Report scope

Global Viral Partnering 2012 to 2018 is intended to provide the reader with an in-depth understanding and access to Viral trends and structure of deals entered into by leading companies worldwide.

Global Viral Partnering 2012 to 2018 includes:

Trends in Viral dealmaking in the biopharma industry since 2012

Analysis of Viral deal structure

Access to headline, upfront, milestone and royalty data

Access to hundreds of Viral deal contract documents

Comprehensive access to over 3500 Viral deal records

The leading Viral deals by value since 2012

Most active Viral dealmakers since 2012

The report includes deals for the following indications:

Viral: Common cold, Cytomegalovirus, Ebola, FIV, Foot and mouth disease, Hepatitis A, B, C, D, Herpes simplex, HIV, Influenza, H5N1 (Avian Flu), H1N1 (Swine Flu), Japanese encephalitis, Polio, Respiratory syncytial virus (RSV), Zika, plus other viral indications.

In Global Viral Partnering 2012 to 2018, available deals and contracts are listed by:

Headline value

Upfront payment value

Royalty rate value

Stage of development at signing

Deal component type

Technology type

Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Viral Partnering 2012 to 2018 report provides comprehensive access to available deals and contract documents for over 1,500 viral deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise viral rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Viral Partnering 2012 to 2018 provides the reader with the following key benefits:

In-depth understanding of Viral deal trends since 2012

Access Viral deal headline, upfront, milestone and royalty data

Research hundreds of actual contracts between Viral partner companies

Comprehensive access to over 750 links to actual Viral deals entered into by the world's biopharma companies

Indepth review of Viral deals entered into by the top 25 most active dealmakers

Benchmark the key deal terms companies have agreed in previous deals

Identify key terms under which companies partner Viral opportunities

Uncover companies actively partnering Viral opportunities

Global Viral Partnering 2012-2018: Deal trends, players and financials

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Viral dealmaking
2.1. Introduction
2.2. Viral partnering over the years
2.3. Viral partnering by deal type
2.4. Viral partnering by industry sector
2.5. Viral partnering by stage of development
2.6. Viral partnering by technology type
2.7. Viral partnering by therapeutic indication

Chapter 3 -Financial deal terms for Viral partnering
3.1. Introduction
3.2. Disclosed financials terms for Viral partnering
3.3. Viral partnering headline values
3.4. Viral deal upfront payments
3.5. Viral deal milestone payments
3.6. Viral royalty rates

Chapter 4 - Leading Viral deals and dealmakers
4.1. Introduction
4.2. Most active in Viral partnering
4.3. List of most active dealmakers in Viral
4.4. Top Viral deals by value

Chapter 5 - Viral contract document directory
5.1. Introduction
5.2. Viral partnering deals where contract document available

Chapter 6 - Viral dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Viral therapeutic target

Appendices
Appendix 1 - Directory of Viral deals by company A-Z 2012 to 2018
Appendix 2 - Directory of Viral deals by deal type 2012 to 2018
Appendix 3 - Directory of Viral deals by stage of development 2012 to 2018
Appendix 4 - Directory of Viral deals by technology type 2012 to 2018
Further reading on dealmaking
Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering

List of Tables and Figures

Figure 1: Viral partnering since 2012
Figure 2: Viral partnering by deal type since 2012
Figure 3: Viral partnering by industry sector since 2012
Figure 4: Viral partnering by stage of development since 2012
Figure 5: Viral partnering by technology type since 2012
Figure 6: Viral partnering by indication since 2012
Figure 7: Viral deals with a headline value
Figure 8: Viral deals with upfront payment values
Figure 9: Viral deals with milestone payment
Figure 10: Viral deals with royalty rates
Figure 11: Active Viral dealmaking activity- 2012 to 2018
Figure 12: Top Viral deals by value since 2012
  • Global Drugs for Vancomycin-Resistant Enterococcus Faecium Market Insights, Forecast to 2025
    Published: 15-Feb-2019        Price: US 3900 Onwards        Pages: 117
    The global Drugs for Vancomycin-Resistant Enterococcus Faecium market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Drugs for Vancomycin-Resistant Enterococcus Faecium market based on company, product type, end user and key regions. This report studies the global market size of Drugs for Vancomycin-Resistant Enterococcus Faecium ......
  • Global Ganciclovir Market Insights, Forecast to 2025
    Published: 15-Feb-2019        Price: US 3900 Onwards        Pages: 117
    The global Ganciclovir market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Ganciclovir market based on company, product type, end user and key regions. This report studies the global market size of Ganciclovir in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on th......
  • Global Clotrimazole Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 15-Feb-2019        Price: US 3480 Onwards        Pages: 115
    Clotrimazole is a white powdered pharmaceutical used for treatment of dermatological and gynaecological fungal infections. Clotrimazole was synthesised in 1969 firstly and its chemical name is 1-[(2-chloro-phenyl)(diphenyl)methyl]-1H-imidazole). Its molecular formula is C22H17ClN2 and the molecular weight is 344.8 g/mol.Clotrimazole is an inhibitor of ergosterol biosynthesis. It has many ecotoxicological properties in common with a range of fungicides used in agriculture. Clotrimazole is a broad......
  • Global Miconazole Nitrate Market Insights, Forecast to 2025
    Published: 15-Feb-2019        Price: US 3900 Onwards        Pages: 117
    Global Miconazole Nitrate market size will increase to Million US$ by 2025, from Million US$ in 2018, at a CAGR of during the forecast period. In this study, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Miconazole Nitrate. This report researches the worldwide Miconazole Nitrate market size (value, capacity, production and consumption) in key regions like United States, Europe, Asia Pacific (China, Japan) and othe......
  • Global Polymixin Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 14-Feb-2019        Price: US 3480 Onwards        Pages: 115
    Polymyxins are antibiotics, with a general structure consisting of a cyclic peptide with a long hydrophobic tail. They disrupt the structure of the bacterial cell membrane by interacting with its phospholipids. They are produced by nonribosomal peptide synthetase systems in Gram-positive bacteria such as Paenibacillus polymyxa and are selectively toxic for Gram-negative bacteria due to their specificity for the lipopolysaccharide molecule that exists within many Gram-negative outer membranes. At......
  • Global Drugs for Herpes Labialis (Oral Herpes) Market Insights, Forecast to 2025
    Published: 14-Feb-2019        Price: US 3900 Onwards        Pages: 122
    Herpes Labialis (Oral Herpes) is a type of herpes simplex occurring on the lip, i.e. an infection caused by herpes simplex virus (HSV). An outbreak typically causes small blisters or sores on or around the mouth. The sores typically heal within 2-3 weeks, but the herpes virus remains dormant in the facial nerves, following orofacial infection, periodically reactivating (in symptomatic people) to create sores in the same area of the mouth or face at the site of the original infection. Herp......
  • Global Infectious Disease Industry Market Research 2019
    Published: 14-Feb-2019        Price: US 2600 Onwards        Pages: 150
    In this report, we analyze the Infectious Disease industry from two aspects. One part is about its production and the other part is about its consumption. In terms of its production, we analyze the production, revenue, gross margin of its main manufacturers and the unit price that they offer in different regions from 2014 to 2019. In terms of its consumption, we analyze the consumption volume, consumption value, sale price, import and export in different regions from 2014 to 2019. We also make a......
  • Global Infectious Disease Treatment Industry Market Research 2019
    Published: 14-Feb-2019        Price: US 2600 Onwards        Pages: 150
    In this report, we analyze the Infectious Disease Treatment industry from two aspects. One part is about its production and the other part is about its consumption. In terms of its production, we analyze the production, revenue, gross margin of its main manufacturers and the unit price that they offer in different regions from 2014 to 2019. In terms of its consumption, we analyze the consumption volume, consumption value, sale price, import and export in different regions from 2014 to 2019. We a......
  • Global Infectious Disease Diagnostics Testing Industry Market Research 2019
    Published: 14-Feb-2019        Price: US 2600 Onwards        Pages: 148
    In this report, we analyze the Infectious Disease Diagnostics Testing industry from two aspects. One part is about its production and the other part is about its consumption. In terms of its production, we analyze the production, revenue, gross margin of its main manufacturers and the unit price that they offer in different regions from 2014 to 2019. In terms of its consumption, we analyze the consumption volume, consumption value, sale price, import and export in different regions from 2014 to ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs